Literature DB >> 8510690

Non-anticoagulant uses of heparin.

D A Lane, L Adams.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8510690     DOI： 10.1056/NEJM199307083290212

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  10 in total

1.  Synthetic mast-cell granules as adjuvants to promote and polarize immunity in lymph nodes.

Authors:  Ashley L St John; Cheryl Y Chan; Herman F Staats; Kam W Leong; Soman N Abraham
Journal:  Nat Mater       Date:  2012-01-22       Impact factor: 43.841

2.  Effect of heparin on the biological properties and molecular signature of human mesenchymal stem cells.

Authors:  Ling Ling; Emily T Camilleri; Torben Helledie; Rebekah M Samsonraj; Drew M Titmarsh; Ren Jie Chua; Oliver Dreesen; Christian Dombrowski; David A Rider; Mario Galindo; Ian Lee; Wanjin Hong; James H Hui; Victor Nurcombe; Andre J van Wijnen; Simon M Cool
Journal:  Gene       Date:  2015-10-17       Impact factor: 3.688

3.  Interaction of heparin with synthetic peptides corresponding to the C-terminal domain of intestinal mucins.

Authors:  G Xu; G G Forstner; J F Forstner
Journal:  Glycoconj J       Date:  1996-02       Impact factor: 2.916

Review 4.  Current recommendations for bladder instillation therapy in the treatment of interstitial cystitis/bladder pain syndrome.

Authors:  Marc A Colaco; Robert J Evans
Journal:  Curr Urol Rep       Date:  2013-10       Impact factor: 3.092

5.  Pharmacokinetics and pharmacodynamics of oral heparin solid dosage form in healthy human subjects.

Authors:  Shaker A Mousa; Fuming Zhang; Ahmad Aljada; Seema Chaturvedi; Majde Takieddin; Haifeng Zhang; Lianli Chi; M Cristina Castelli; Kristen Friedman; Michael M Goldberg; Robert J Linhardt
Journal:  J Clin Pharmacol       Date:  2007-12       Impact factor: 3.126

6.  Heparin at low concentration acts as antivenom against Bothrops jararacussu venom and bothropstoxin-I neurotoxic and myotoxic actions.

Authors:  Sandro Rostelato-Ferreira; Gildo Bernardo Leite; Adélia Cristina Oliveira Cintra; Maria Alice da Cruz-Höfling; Léa Rodrigues-Simioni; Yoko Oshima-Franco
Journal:  J Venom Res       Date:  2010-10-15

7.  Comparison of the Effects of Enoxaparin and Heparin on Inflammatory Biomarkers in Patients with ST-segment Elevated Myocardial Infarction: A prospective Open Label Pilot Clinical Trial.

Authors:  Somayyeh Nasiripour; Kheirollah Gholami; Sarah Mousavi; Abbas Mohagheghi; Mania Radfar; Mohammad Abdollahi; Zahra Khazaeipour; Mojtaba Mojtahedzadeh
Journal:  Iran J Pharm Res       Date:  2014       Impact factor: 1.696

8.  Therapeutic effects of adipose-derived mesenchymal stem/stromal cells with enhanced migration ability and hepatocyte growth factor secretion by low-molecular-weight heparin treatment in bleomycin-induced mouse models of systemic sclerosis.

Authors:  Takayasu Suzuka; Takuya Kotani; Takashi Saito; Shogo Matsuda; Takako Sato; Tohru Takeuchi
Journal:  Arthritis Res Ther       Date:  2022-10-07       Impact factor: 5.606

Review 9.  Current guidelines in the management of interstitial cystitis.

Authors:  Marc Colaco; Robert Evans
Journal:  Transl Androl Urol       Date:  2015-12

Review 10.  Review of intravesical therapies for bladder pain syndrome/interstitial cystitis.

Authors:  Kristina Cvach; Anna Rosamilia
Journal:  Transl Androl Urol       Date:  2015-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.